Over the past 15 years, outsourcing of biologics has continued to increase steadily at a rate of around 4% annually. This is already accelerating, at least in the near-term, as the current Covid-19 crisis changes the dynamics of bioprocessing. According to BioPlan Associates, 65% of biotherapeutic facilities use contract development and manufacturing organization (CDMO) services for at least some of their bioprocessing. In addition, 70% of biopharma decision-makers expect to do more outsourcing, and 60% will change their supply chain strategies as a long-term result of the Covid-19 pandemic. In this webinar, BioPlan’s Eric Langer will explore how the landscape for both supply chain managers and contract manufacturers will evolve as a result.